Merck & Company Inc (MRK)vsQ32 Bio Inc (QTTB)
MRK
Merck & Company Inc
$146.73
-0.14%
HEALTHCARE · Cap: $368.89B
QTTB
Q32 Bio Inc
$9.25
+4.52%
HEALTHCARE · Cap: $257.51M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 125285% more annual revenue ($67.38B vs $53.74M). QTTB leads profitability with a 62.9% profit margin vs 3.6%. QTTB trades at a lower P/E of 2.8x. QTTB earns a higher WallStSmart Score of 54/100 (C-).
MRK
Hold44
out of 100
Grade: D
QTTB
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-72.9%
Fair Value
$84.87
Current Price
$146.73
$61.86 premium
Margin of Safety
+87.5%
Fair Value
$30.73
Current Price
$9.25
$21.48 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 41.2%
Generating 5.5B in free cash flow
Attractively priced relative to earnings
Every $100 of equity generates 32 in profit
Keeps 63 of every $100 in revenue as profit
Strong operational efficiency at 39.9%
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Trading at 8.6x book value
4.7% revenue growth
ROE of 5.5% — below average capital efficiency
3.6% margin — thin
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : QTTB
The strongest argument for QTTB centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 62.9% and operating margin at 39.9%.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Revenue Growth, Return on Equity. A P/E of 151.0x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Bear Case : QTTB
The primary concerns for QTTB are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
MRK carries more volatility with a beta of 0.22 — expect wider price swings.
MRK is growing revenue faster at 4.7% — sustainability is the question.
MRK generates stronger free cash flow (5.5B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
QTTB scores higher overall (54/100 vs 44/100), backed by strong 62.9% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Q32 Bio Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Q32 Bio Inc. (QTTB) is a pioneering biotechnology firm focused on the development of advanced antibody-based therapies for autoimmune diseases and immune response optimization. Leveraging its proprietary technology platform, the company is building a robust pipeline of therapeutic candidates designed to restore immune balance and tackle significant unmet medical needs. Guided by a seasoned management team and reinforced by strategic collaborations, Q32 Bio is well-positioned to make impactful contributions to healthcare and generate substantial long-term value for its shareholders through dedicated research and development initiatives.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?